Switzerland Approves Study Examining Effects of Controlled Purchases of Cannabis
The study will examine consumption and health of the participants after purchasing selected cannabis products from controlled cultivation under regulated conditions.
On March 21, 2023, the study titled “Züri Can–Cannabis with responsibility,” created by the City of Zurich and the University of Zurich, met approval and opened its registration process, after being postponed in 2022. “The study examines the effects of purchasing selected cannabis products from controlled cultivation under regulated conditions on the consumption and health of the participants,” read the study, translated from German (1). “In addition, different models of regulated cannabis procurement are to be compared with one another.”
The sale of cannabis products for the study will begin at the preestablished supply points after the summer holidays, and only organic and local products will be permitted (1). Currently, cannabis products containing less than 1% THC are permitted in Switzerland under limited instances (2).
“As a study participant, you will contribute to research into a possible regulation of cannabis consumption in Switzerland,” read the consent form in part, translated from German (3). “If you meet the eligibility requirements below and are included in the study, you can legally purchase cannabis for personal use for three years under regulated conditions. As a study participant, you must fill out a scientific online questionnaire at regular intervals.”
Scientific, approved pilot trials of controlled sales of cannabis for recreational purposes were first allowed in 2021 (4). Future studies with public and university sponsors are planned for several more cities in Switzerland (1).
References
- https://www.stadt-zuerich.ch/portal/de/index/politik_u_recht/stadtrat/weitere-politikfelder/drogen-suchtpolitik/studien-und-projekte/cannabisprojekt-der-stadt-zuerich/wissenswertes-zur-cannabis-studie.html
- https://www.ch.ch/en/health/medicines-and-narcotic-substances/cannabis/#when-is-cannabis-an-illegal-drug
- https://www.stadt-zuerich.ch/portal/de/index/politik_u_recht/stadtrat/weitere-politikfelder/drogen-suchtpolitik/studien-und-projekte/cannabisprojekt-der-stadt-zuerich/konsumierende.html
- https://www.stadt-zuerich.ch/portal/de/index/politik_u_recht/stadtrat/weitere-politikfelder/drogen-suchtpolitik/studien-und-projekte/cannabisprojekt-der-stadt-zuerich.html#
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
